We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase ...

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

Fintel reports that on May 29, 2025, Goldman Sachs initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data from select pipeline candidates across the Company's diversified oncology portfolio ...